Điều trị Dược phẩm cho Rối loạn Tự kỷ: Một Đánh giá và Cách tiếp cận Lâm sàng

Accreditation Council on Services for People with Disabilities. (1993). Outcome Based Performance Measures, Accreditation Council, Landover, MD.

Adler, L., Preslow, E., Rotrosen, J., Duncan, E., Lee, M., Rosenthal, M., and Angrist, B. (1993). Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry 150: 1405-1407.

Aman, M. G. (1982). Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. J. Autism Dev. Disord. 12: 385-398.

Aman, M. G., Bourgondien, M. D., Wolford, P. L., and Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. J. Am. Acad. Child Adolesc. Psychiatry 34: 1672-1681.

Aman, M. G., Sarphare, G., and Burrow, W. (1995). Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. Am. J. Ment. Retard. 99: 500-599.

American Academy of Pediatrics Committee on Nutrition. (1976). Megavitamin therapy for childhood psychoses and learning disabilities. Pediatrics 58: 910-912.

American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th edn., American Psychiatric Association, Washington, DC.

Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., and Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am. J. Psychiatry 141: 1195-1202.

Angold, A., and Costello, E. (1993). Depressive comorbidity in children and adolescents: Empirical, theoretical, and methodological issues. Am. J. Psychiatry 150: 1779-1791.

August, G. J., Raz, N., and Baird, T. D. (1985). Effects of fenfluramine on behavioral, cognitive, and affective disturbances in autistic children. J. Autism Dev. Disord. 15: 97-105.

Baron-Cohen, S., Mortimore, C., Moriarty, J., Izaguirre, J., and Robertson, M. (1999). The prevalence of Gilles de la Tourette's syndrome in children and adolescents with autism. J. Child Psychol. Psychiatry 40: 213-218.

Bender, L. (1947). One hundred cases of childhood schizophrenia treated with electric shock. Trans. Am. Neurol. Assoc. 72: 165-169.

Biederman, J. (1998). Attention-deficit/hyperactivity disorder: A life-span perspective. J. Clin. Psychol. Psychiatry 59(Suppl. 7): 4-16.

Birmaher, B., Quintana, H., and Greenhill, L. L. (1988). Methylphenidate treatment of hyperactive autistic children. J. Am. Acad. Child Adolesc. Psychiatry 27: 248-251.

Brasic, J. R., Barnett, J. Y., Kaplan, D., Sheitman, B. B., Aisemberg, P., Lafargue, R. T., Kowalik, S., Clark, A., Tsaltas, M. O., and Young, J. G. (1994). Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 44: 1309-1312.

Brasic, J. R., Barnett, J. Y., Sheitman, B. B., Lafargue, R. T., Kowalik, S., Kaplan, D., Tsaltas, M. O., Ahamad, R., Nadrich, R. H., and Mendonca, M.de F. (1998). Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. CNS Spectrums 3: 39-46.

Burd, L., Fisher, W., and Kerbeshian, J. (1985). Pervasive developmental disorders in multiply disabled children. Rehab. Lit. 46: 9, 10.

Burd, L., Fisher, W., Vesely, B., Williams, M., Kerbeshian, J., and Leech, C. (1991). Prevalence of psychoactive drug use among North Dakota group home residents. Am. J. Ment. Retard. 96: 119-126.

Burd, L., Williams, M. G., Klug, M. G., Fjelstad, K., Schimke, A., and Kerbeshian, J. (1997). Prevalence of psychotropic and anticonvulsant drug use among North Dakota group home residents. J. Intellect. Disab. Res. 41: 488-494.

Campbell, M. (1988). Annotation: Fenfluramine treatment of autism. J. Child Psychol. Psychiatry 29: 1-10.

Campbell, M., Adams, P., Perry, R., Spencer, E. K., and Overall, J. E. (1988). Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacol. Bull. 24: 251-255.

Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., and Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. J. Am. Acad. Child Adolesc. Psychiatry 32: 1283-1291.

Campbell, M., Anderson, L. T., Small, A. M., Perry, R., Green, W. H., and Caplan, R. (1982). The effects of haloperidol on learning and behavior in autistic children. J.Aut. Dev. Disord. 12: 167-175.

Campbell, M., Cohen, I. L., and Anderson, L. T. (1981). Pharmacotherapy for autistic children: Summary of research. Can. J. Psychiatry 26: 265-273.

Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., and Koh, C. (1972a). Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children. J. Autism Child Schiz. 2: 343-358.

Campbell, M., Fish, B., Korein, J., Shapiro, T., Collins, P., and Koh, C. (1972b). Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J. Autism Child Schiz. 2: 234-263.

Campbell, M., Rapoport, J. L., and Simpson, G. M. (1999). Antipsychotics in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38: 537-545.

Chappell, P. B., Riddle, M. A., Scahill, L., Lynch, K. A., Schultz, R., Arnsten, A., Leckman, J. F., and Cohen, D. J. (1995). Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. J. Am. Acad. Child Adolesc. Psychiatry 34: 1140-1146.

Chez, M. G., Buchanan, C. P., Bagan, B. T., Hammer, M. S., McCarthy, K. S., Ovrutskaya, I., Nowinski, C. V., and Cohen, A. S. (2000). Secretin and autism: A two-part clinical investigation. J. Autism Dev. Disord. 30: 87-94.

Clarkin, J. F., and Kendall, P. C. (1992). Comorbidity and treatment planning: Summary and future directions. J. Consult. Clin. Psychol. 60: 904-908.

Connor, D. F., and Posever, T.A. (1998). A brief review of atypical antipsychotics in individuals with developmental disability. Ment. Health Aspects Dev. Disab. 1: 93-102.

Cook, E. H. (1990). Autism: Review of neurochemical investigation. Synapse 6: 292-308.

Cook, E. H. Jr., Rowlett, R., Jaselskis, C., and Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 31: 739-745.

Dales, L., Hammer, S. J., and Smith, N. J. (2001). Time trends in autism and in MMR immunization coverage in California. J. Am. Med. Assoc. 285: 1183-1185.

Daly, J. M., and Wilens, T. (1998). The use of tricyclic antidepressants in children and adolescents. Pediatr. Clin. N. Am. 45: 1123-1135.

Dartnall, N. A., Holmes, J. P., Morgan, S. N., and McDougle, S. J. (1999). Brief report: Two-year control of behavioral symptoms with risperidone in two profoundly regarded adults with autism. J. Autism Dev. Disord. 29: 87-91.

DeLong, G. R. (1994). Children with autistic spectrum disorder and a family history of affective disorder. Dev. Med. Child Neurol. 36: 674-688.

DeLong, G. R., Teague, L. A., and Kamran, M. McS. (1998). Effects of fluoxetine treatment in young children with idiopathic autism. Dev. Med. Child Neurol. 40: 551-562.

Dunn-Geier, J., Ho, H. H., Auersperg, E., Doyle, D., Eaves, L., Matsuba, C., Orrbine, E., Pham, B., and Whiting, S. (2000). Effect of secretin on children with autism:Arandomized controlled trial. Dev. Med. Child Neurol. 42: 796-802.

Eisenberg, L., and Kanner, L. (1956). Early infantile autism, 1943-1955. Am. J. Orthopsychiatry 26: 556-566.

Emslie, G. J., Walkup, J. T., Pliszka, S. R., and Ernst, M. (1999). Nontricyclic antidepressants: Current trends in children adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38: 517-528.

Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science 196: 129-136.

Feldman, H., Crumrine, P., Handen, B. L., Alvin, R., and Teodori, J. (1989). Methylphenidate in children with seizures and attention-deficit disorder. Am. J. Dis. Child. 143: 1081-1086.

Feldman, H. M., Kolmen, B. K., and Gonzaga, A. D. (1999). Naltrexone and communication skills in young children with autism. J. Am. Acad. Child Adolesc. Psychiatry 38: 587-593.

Findling, R. L., and Dogin, J.W. (1998). Psychopharmacology of ADHD: Children and adolescents. J. Clin. Psychiatry 59(Suppl. 7): 42-49.

Findling, R. L., Maxwell, K., Scotese-Wojtila, L., Huang, J., Yamashita, T., and Wiznitzer, M. (1997). High-dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double-blind placebo controlled study. J. Autism Dev. Disord. 27: 467-478.

Findling, R. L., Schulz, S. C., Reed, M. D., and Blumer, J. L. (1998). The antipsychotics: A pediatric perspective. Pediatr. Clin. N. Am. 45: 1205-1232.

Fish, B., Shapiro, T., and Campbell, M. (1966). Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am. J. Psychiatry 123: 32-39.

Fisher, W., Burd, L., and Kerbeshian, J. (1985). Integrating developmental, pharmacologic, and psychological diagnoses and management through the transdisciplinary team process. Rehab. Lit. 46: 268-270.

Fisher, W., Kerbeshian, J., and Burd, L. (1986).A treatable language disorder: Pharmacological treatment of pervasive developmental disorder. Dev. Behav. Pediatr. 7: 73-75.

Fisher, W., Piazza, C., and Page, T. J. (1989). Assessing independent and interactive effects of behavioral and pharmacologic interventions for a client with dual diagnoses. J. Behav. Ther. Exp. Psychiatry 20: 241-250.

Freedman, A. M. (1958). Treatment of autistic schizophrenic children with marsilid. J. Clin. Exp. Psychopathol. Q. Rev. Psychiatry Neurol. Spec. Suppl. 19: 138-145.

Freedman, A. M., Ebin, E. V., and Wilson, E. A. (1962). Autistic schizophrenic children: An experiment in the use of d-lysergic acid diethylamide (LSD-25). Arch. Gen. Psychiatry 6: 203-213.

Gadow, K. D. (1997). An overview of three decades of research in pediatric psychopharmacology. J. Child Adolesc. Psychopharmacol. 7: 219-236.

Geller, B., Reising, D., Leonard, H. L., Riddle, M. A., and Walsh, B. T. (1999). Critical review of tricyclic antidepressant use in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38: 513-516.

Geller, E., Ritvo, E. R., Freeman, B. J., and Yuwiler, A. (1982). Preliminary observations on effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N. Engl. J. Med. 307: 165-169.

Ghaziuddin, M., Tsai, L., and Ghaziuddin, N. (1991). Fluoxetine in autism with depression. J. Am. Acad. Child Adolesc. Psychiatry 30: 508-509.

Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., and Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am. J. Psychiatry 149: 363-366.

Greenhill, L. L., Halperin, J. M., and Abikoff, H. (1999). Stimulant medications. J. Am. Acad. Child Adolesc. Psychiatry 38: 503-512.

Gualtieri, C. T. (1986). Fenfluramine and autism: Careful reappraisal is in order. J. Pediatr. 108: 417-419.

Gutgessell, H., Atkins, D., Barst, R., Buck, M., Franklin, W., Humes, R., Ringel, R., Shaddy, R., and Taubert, K. A. (1999). AHA scientific statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation 99: 979-982.

Hagerman, R. J. (1996). Fragile X-syndrome. Child Adolesc. Psychiatry Clin. N. Am. 5: 895-911.

Hammock, R. G., Schroeder, S. R., and Levine, W. R. (1995). The effect of clozapine on selfinjurious behavior. J. Autism Dev. Disord. 25: 611-626.

Handen, B. L., Janosky, J., McAuliffe, S., Breaux, A. M., and Feldman, H. (1994). Prediction of response to methylphenidate among children with ADHD and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 33: 1185-1193.

Hillebrand, M., and Scott, K. (1995). The use of buspirone with aggressive behavior. J. Autism Dev. Disord 25: 663-664.

Ho, H. H., Lockitch, G., Eaves, L., and Jacobson, B. (1986). Blood serotonin concentrations and fenfluramine therapy in autistic children. J. Pediatr. 108: 465-469.

Hollander, E., Kaplan, A., Cartwright, C., and Reichman, D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. J. Child Neurol. 15: 132-135.

Holzer, J. C., Gitelman, D. R., and Price, B. H. (1995). Efficacy of busprione in the treatment of dementia. Am. J. Psychiatry 152: 812.

Horrigan, J. P., and Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. J. Autism Dev. Disord. 27: 313-323.

Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R., Nabors, L., and Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorder. J. Assoc. Acad. Min. Physicians 9: 9-15.

Jaselskis, C. A., Cook, E. H., Fletcher, K. E., and Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. J. Clin. Psychopharmacol. 12: 322-327.

Kanner, L. (1943). Autistic disturbances of affective contact. Ner. Child 2: 217-250.

Kanner, L. (1948). Child Psychiatry, Charles C Thomas, Springfield, IL.

Kaplan, H. I., and Sadock, B. J. (1993). Pocket Handbook of Psychiatric Drug Treatment, Williams and Wilkins, Baltimore.

Kerbeshian, J., and Burd, L. (1987). Are schizophreniform symptoms present in attenuated form in children with Tourette disorder and other developmental disorders. Can. J. Psychiatry 32: 123-135.

Kerbeshian, J., and Burd, L. (1988). A clinical pharmacological approach to treating Tourette syndrome in children and adolescents. Neurosci. Biobehav. Rev. 12: 241-245.

Kerbeshian, J., and Burd, L. (1991). A clinical pharmacological approach to the treatment of autism. Habilitative Ment. Health Care Newsletter 10: 33-36.

Kerbeshian, J., and Burd, L. (1992). Epidemiology and comorbidity: The North Dakota prevalence studies of Tourette syndrome and other developmental disorders. In Chase, T. N., Friedhoff, A. J., and Cohen, D. J. (eds.), Advances in Neurology, 58th edn., Raven Press, New York, pp. 67-74.

Kerbeshian, J., and Burd, L. (1996). Case study: Comorbidity among Tourette's syndrome, autistic disorder, and bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 35: 681-685.

Kerbeshian, J., Burd, L., and Fisher, W. (1987). Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J. Clin. Psychopharmacol. 7: 401-405.

Kerbeshian, J., Burd, L., Randall, T., Martsolf, J., and Jalal, S. (1990). Autism, profound mental retardation and atypical bipolar disorder in a 33-year-old female with a deletion of 15q12. J. Ment. Def. Res. 34: 205-210.

Kolmen, B. K., Feldman, H. M., Handen, B. L., and Janosky, J. E. (1997). Naltrexone in young autistic children: Replication study and learning measures. J. Am. Acad. Child Adolesc. Psychiatry 36: 1570-1578.

Koshes, R. J., and Rock, N. J. (1994). Use of clonidine for behavioral control in an adult patient with autism. Am. J. Psychiatry 151: 1714.

Lancet (2000). Measles, MMR, and autism: The confusion continues [Editorial]. Lancet 355: 1379.

Leboyer, M., Bouvard, M. P., Launay, J., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., and Panksepp, J. (1992). Brief report: A double-blind study of naltrexone in infantile autism. J. Autism Dev. Disord. 22: 309-319.

Malek-Ahmadi, P., and Simonds, J. F. (1998). Olanzapine for autistic disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry 37: 902.

Marangell, L.B. (2000). Augmentation of standard depression therapy. Clin. Ther. 22(Suppl. A): A235-A238.

Martin, A., Koenig, K., Scahill, L., and Bregman, J. (1999a). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J. Child Adolesc. Psychopharmacol. 9: 99-107.

Martin, A., Scahill, L., Klin, A., and Volkmar, F. R. (1999b). Higher-functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. J. Am. Acad. Child Adolesc. Psychiatry 38: 923-931.

Martineau, J., Barthelemy, C., Garreau, B., and Lelord,G. (1985). Vitamin B6, magnesium, and combined B6-Mg: Therapeutic effects in childhood autism. Biol. Psychiatry 20: 467-478.

McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., and Price, L. H. (1998a). Sertraline in adults with pervasive developmental disorders: A prospective openlabel investigation. J. Clin. Psychopharmacol. 18: 62-66.

McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., and Price, L. H. (1998b). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 55: 633-641.

McDougle, C. J., Kresch, L. E., Goodman, W. K., Naylor, S. T., Volkmar, F. R., Cohen, D. J., and Price, L. H. (1995). A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am. J. Psychiatry 152: 772-777.

McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., and Price, L. H. (1996).A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen. Psychiatry 53: 1001-1008.

McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O'Brien, D., Nielsen, J., Bregman, J., and Cohen, D. J. (1992). Clomipramine in autism: Preliminary evidence of efficacy. J. Am. Acad. Child Adolesc. Psychiatry 31: 746-750.

McDougle, C. J., Scahill, L., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Freeman, B. J., Martin, A., McGough, J. J., Cronin, P., Posey, D. J., Riddle, M. A., Ritz, L., Swiezy, N. B., Vitiello, B., Volkmar, F. R., Votolato, N. A., and Walson, P. (2000). Research units on pediatric psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc. Psychiatr. Clin. N. Am. 9: 201-224.

Minshew, J. N. (1991). Indices of neural function in autism: Clinical and biological implications. Pediatrics 87: 774-780.

Minshew, N. J. (1996). Brief report. Brain mechanisms in autism: Functional and structural abnormalities. J. Autism Dev. Disord. 26: 205-209.

Nicolson, R., Awad, G., and Sloman, L. (1998). An open trial of risperidone in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 37: 372-376.

Olsson, I., Steffenburg, S., and Gillberg, C. (1988). Epilepsy in autism and autisticlike conditions: A population-based study. Arch. Neurol. 45: 666-668.

Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., and Overall, J. E. (1989). Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J. Am. Acad. Child Adolesc. Psychiatry 28: 87-92.

Petty, L. K., Ornitz, E. M., Michelman, J. D., and Zimmerman, E. G. (1984). Autistic children who become schizophrenic. Arch. Gen. Psychiatry 41: 129-135.

Posey, D. J., Litwiller, M., Koburn, A., and McDougle, C. J. (1999a). Paroxetine in autism. J. Am. Acad. Child Adolesc. Psychiatry 38: 111-112.

Posey, D. J., Walsh, K. H., Wilson, G. A., and McDougle, C. J. (1999b). Risperidone in the treatment of two very young children with autism. J. Child Adolesc. Psychopharmacol. 9: 273-276.

Potenza, M. N., Holmes, J. P., Kanes, S. J., and McDougle, C. J. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: And open-label pilot study. J. Clin. Psychopharmacol. 19: 37-44.

Ratey, J. J., Bemporad, J., Sorgi, P., Bick, P., Polakoff, S., O'Driscoll, G., and Mikkelsen, E. (1987). Brief report: Open trial effects of beta blockers on speech and social behaviors in 8 autistic adults. J. Autism Dev. Disorders 17: 439-446.

Ratey, J., Sovner, R., Mikkelsen, E., and Chmielinski, H. (1989). Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J. Clin. Psychiatry 50: 382-384.

Realmuto, G., August, G., and Garfinkel, B. (1989). Clinical effect of buspirone in autistic children. J. Clin. Psychopharmacol. 9: 122-125.

Riddle, M. A., Bernstein, G. A., Cook, W. H., Leonard, H. L., March, J. S., and Swanson, J. M. (1999). Anxiolytics, adrenergic agents, and naltrexone. J. Am. Acad. Child Adolesc. Psychiatry 38: 546-556.

Rimland, B. (1988). Controversies in the treatment of autistic children: Vitamin and drug therapy. J. Child Neurol. 3: S68-S72.

Rimland, B. (1998). High dose vitamin B6 and magnesium in treating autism: Response to study by Findling et al. J. Autism Dev. Disord. 28: 581-582.

Rozovsky, F. (1990). Consent to Treatment: A Practical Guide, Little, Brown, and Co., Boston.

Ryan, N. D., Bhatara, V. S., and Perel, J. M. (1999). Mood stabilizers in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38: 529-536.

Sahley, T. L., and Panksepp, J. (1987). Brain opioids and autism: An updated analysis of possible linkages. J. Autism Dev. Disord. 17: 201-216.

Sanchez, L. E., Campbell, M., Small, A. M., Cueva, J. E., Armenteros, J. L., and Adams, P. B. (1996). A pilot study of clomipramine in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry 35: 537-544.

Sandler, A. D., Sutton, K. A., DeWeese, J., Girard, M. A., Sheppard, V., and Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N. Engl. J. Med. 341: 1801-1806.

Shenoy, S., Arnold, S., and Chatila, T. (2000). Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J. Pediatr. 136: 682-687.

Sherman, J., Factor, D. C., Swinson, R., and Darjes, R. W. (1989). The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J. Autism Dev. Disord. 19: 533-543.

Snead, B. E., Boon, F., and Presberg, J. (1994). Paroxetine for self-injurious behavior. J. Am. Acad. Child Adolesc. Psychiatry 35: 4099-4432.

Sovner, R. (1990). Bipolar disorder in persons with developmental disorders: An overview. In Dosen, A., and Menolascino, F. J. (eds.), Depression in Mentally Retarded Children and Adults, Logan, Leiden, the Netherlands, pp. 175-198.

Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., and Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry 35: 127-129.

Stefanatos, G. A., Grover, W., and Geller, E. (1995). Case study: Corticosteroid treatment of language regression in pervasive developmental disorder. J. Am. Acad. Child Adolesc. Psychiatry 34: 1107-1111.

Steingard, R., and Biederman, J. (1987). Case report: Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 26: 932-935.

Sverd, J., and Montero, G. (1993). Brief report: Cases for an association between Tourette syndrome, autistic disorder, and schizophrenia-like disorder. J. Autism Dev. Disord. 23: 407-413.

Taylor, B., Miller, E., Farrington, C. P., Petropoulos, M. C., Favot-Mayaud, I., Li, J., and Waight, P. A. (1999). Autism and measles, mumps and rubella vaccine: No epidemiological evidence for a causal association. Lancet 353: 2026-2029.

Volkmar, F. R. (1999). Lessons from secretin. N. Engl. J. Med. 341: 1842-1843.

Volkmar, F. R., and Nelson, D. S. (1990). Seizure disorders in autism. J. Am. Acad. Child Adolesc. Psychiatry 29: 127-129.

Volkmar, F. R., Paul, R., Cohen, D. J., and Shaywitz, B. A. (1983). Irritability in autistic children treated with fenfluramine. N. Engl. J. Med. 309: 187.

Wakefield, A. J., Murch, S. H., Anthony, A., Linnell, J., Casson, D. M., Malik, M., Berelowitz, M., Dhillon, A. P., Thomson, M. A., Harvey, P., Valentine, A., Davies, S. E., and Walker-Smith, J. A. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351: 637-641.

Walters, A. S., Rowland, P. B., Feinstein, C., Mercurio, A., and Hole, W. T. (1990). A case report of naltrexone treatment of self-injury and social withdrawal in autism. J. Autism Dev. Disord. 20: 169-176.

Wilens, T. E., Biederman, J., Baldessarini, R. J., Geller, B., Schleifer, D., Spencer, J. J., Birmaher, B., and Goldblatt, A. (1996). Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 35: 1491-1501.

Willemsen-Swinkels, S. H. N., Buitelaar, J. K., Nijhof, G. J., and van Engeland, H. (1995). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Arch. Gen. Psychiatry 54: 766-773.

Zudda, A., DiMartino, A., Muglia, P., and Cianchetti, C. (2000). Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. J. Child Adolesc. Psychopharmacol. 10: 79-90.